Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.67 USD | +1.35% | -2.67% | +31.94% |
09/05 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
08/05 | Revolution Medicines Q1 Net Loss Narrows | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.94% | 6.13B | |
+29.77% | 48.16B | |
-1.02% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.16% | 25.59B | |
-23.07% | 18.96B | |
+8.51% | 12.92B | |
+28.77% | 12.03B | |
-1.92% | 11.77B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Goldman Sachs Adjusts Revolution Medicines' Price Target to $20 From $19, Keeps Neutral Rating